Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55.7M
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
14.2M
-
Shares change
-
-250K
-
Total reported value, excl. options
-
$20.6M
-
Value change
-
-$483K
-
Number of buys
-
15
-
Number of sells
-
-17
-
Price
-
$1.45
Significant Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q1 2023
59 filings reported holding SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2023.
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.2M shares
of 55.7M outstanding shares and own 25.58% of the company stock.
Largest 10 shareholders include Anson Funds Management LP (3.34M shares), VANGUARD GROUP INC (1.43M shares), Atlas Venture Associates IX, LLC (1.38M shares), AWM Investment Company, Inc. (1.3M shares), Atlas Venture Life Science Advisors, LLC (1.03M shares), Alphabet Inc. (890K shares), Murchinson Ltd. (806K shares), Rock Springs Capital Management LP (670K shares), MILLENNIUM MANAGEMENT LLC (495K shares), and BlackRock Inc. (490K shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.